Molecule News and Research

RSS

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. today announced that treatment with its lead compound, Homspera, in combination with a DNA vaccine utilizing Scancell's ImmunoBody technology significantly improved the immune response of the vaccine in an animal model.

8 Sep 2010

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).

8 Sep 2010

NGP 555 compound effective in preventing amyloid pathology of Alzheimer's disease

In the Sept. 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model.

8 Sep 2010

Researchers develop new RNA molecule approach to kill cancer cells

Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. The process developed by Niles Pierce, associate professor of applied and computational mathematics and bioengineering at Caltech, and his colleagues uses small RNA molecules that can be programmed to attack only specific cancer cells then, by changing shape, those molecules cause the cancer cells to self destruct.

8 Sep 2010

University of Maryland School of Medicine orders AVANCE III 950 US2 NMR spectrometer from Bruker

Bruker Corporation announces a major order from the University of Maryland School of Medicine for its ultra-high field AVANCE III 950 US2 NMR spectrometer. The 950 MHz Nuclear Magnetic Resonance magnet and spectrometer will help University of Maryland researchers to unravel the mysteries of molecules and develop new agents to treat cancer, AIDS and other diseases.

7 Sep 2010

Risk of late onset TRAS in living unrelated donor kidney recipients

Patients who have received a new kidney are significantly more likely to develop transplant renal artery stenosis (TRAS) if they are obese or over 50, according to research published in the September issue of the Journal of Renal Care.

7 Sep 2010

Researchers to develop new treatment strategy for cancer

Cancer is a difficult disease to treat because it's a personal disease. Each case is unique and based on a combination of environmental and genetic factors. Conventional chemotherapy employs treatment with one or more drugs, assuming that these medicines are able to both "diagnose" and "treat" the affected cells. Many of the side effects experienced by chemotherapy patients are due to the fact that the drugs they are taking aren't selective enough.

7 Sep 2010

Study on bacteria may help to develop treatment method for osteomyelitis

A surface molecule on bacteria that instructs bone cells to die could be the target for new treatments for bone disease, says a scientist speaking at the Society for General Microbiology's autumn meeting today.

7 Sep 2010

MIT develops safer, simpler way to attach phosphorus to organic compounds

Phosphorus, a mineral element found in rocks and bone, is a critical ingredient in fertilizers, pesticides, detergents and other industrial and household chemicals. Once phosphorus is mined from rocks, getting it into these products is hazardous and expensive, and chemists have been trying to streamline the process for decades.

4 Sep 2010

RIFM publishes special issue on safety assessment of unsaturated alcohols

The Research Institute for Fragrance Materials, Inc. (RIFM) has now published on the RIFM web site, in the Publications section, a special issue of Food and Chemical Toxicology, Volume 48, Supplement 3, on the RIFM Human Health Group Summary, A Safety Assessment of Non-cyclic Alcohols with Unsaturated Branched Chain when used as Fragrance Ingredients.

4 Sep 2010

Emerald BioStructures, SomaLogic announce strategic collaboration for SOMAmers

Emerald BioStructures, a leading provider of integrated structural biology services, and SomaLogic, Inc., a diagnostics and biomarker discovery company, today announced that they have entered into a strategic collaboration for the structure-based design of chemically modified DNA aptamers and small molecule therapeutics, based on crystal structures of important protein targets bound to high affinity SOMAmers.

3 Sep 2010

ForteBio launches Protein G biosensor for rapid detection of mammalian IgGs

ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution. Because it runs on the company's label-free Octet instrumentation platform, the new biosensor enables such measurements with unprecedented speed, ease of use and cost-efficiency.

3 Sep 2010

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

Celldex Therapeutics, Inc. announced today it will regain full worldwide rights to develop and commercialize rindopepimut (CDX-110), effective November 1, 2010.

3 Sep 2010

Research on immune system can develop new therapy for inflammation, tumors

In two closely related studies, two teams of Scripps Research Institute scientists have discovered the underlying mechanisms that activate a type of immune cell in the skin and other organs. The findings may lead to the development of new therapies to treat inflammation, wounds, asthma, and malignant tumors.

3 Sep 2010

Scientists discover how omega-3 fatty acids shut down inflammation and reverse diabetes

Fish oil is touted for its anti-inflammatory and anti-diabetic benefits, but scientist weren't sure how the omega-3 fatty acids in fish oil work. Now, according to a report in the September 3rd issue of the journal Cell, scientists have nailed how omega-3 fatty acids both shut down inflammation and reverse diabetes in obese mice.

3 Sep 2010

Millennium publishes article on MLN4924 pathway mechanism in lymphoma

Millennium, The Takeda Oncology Company today announced the publication of an article in the journal Blood describing the novel mechanism of action of MLN4924 through targeted pathway modulation in diffuse large B-cell lymphoma (DLBCL).

3 Sep 2010

Researchers discover new class of edible nanostructures for energy storage

Sugar, salt, alcohol and a little serendipity led a Northwestern University research team to discover a new class of nanostructures that could be used for gas storage and food and medical technologies. And the compounds are edible.

3 Sep 2010

Researchers clear hurdle on path toward gene-therapy treatment for disease

One of the most difficult aspects of working at the nanoscale is actually seeing the object being worked on. Biological structures like viruses, which are smaller than the wavelength of light, are invisible to standard optical microscopes and difficult to capture in their native form with other imaging techniques.

2 Sep 2010

Researcher awarded $1.8M grant to investigate sex differences in anxiety

Anxiety disorders afflict women twice as often as men, but estrogen might not be the reason. Testosterone, though, could be. That is one of the preliminary findings in the lab of Florida State University researcher Mohamed Kabbaj, associate professor in the College of Medicine. He recently was awarded a five-year, $1.8 million grant from the National Institute of Mental Health to investigate the sex differences in anxiety.

2 Sep 2010

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Nabi Biopharmaceuticals announced today that it has entered into a long-term commercial manufacturing agreement with Diosynth RTP, Inc. for the manufacture of Drug Substance integral to the production of NicVAX, Nabi's innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse.

2 Sep 2010